Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongzhi Surunjiang Capsule is a traditional Uighur herbal medicine developed by Xinjiang Uighur Pharmaceutical Co., Ltd. It is formulated based on the ancient Uyghur medical text 'Karzhibadin Kadeer' and contains seven herbal ingredients: Senna, Colchicum, Terminalia chebula, box fruit vine (Operculina turpethum), almond (Prunus amygdalus), saffron (Crocus sativus), and Scammony resin. The medicine is primarily used for the treatment of acute gouty arthritis and various rheumatic conditions. Its therapeutic effects are attributed to its ability to reduce inflammatory markers such as ESR and C-reactive protein, and suppress the expression of inflammatory cytokines including IL-1β and TNF-α, likely through the inhibition of the NLRP3 inflammasome pathway. It is approved in China and is included in the National Medical Insurance list.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongzhi Surunjiang Capsule.